# US 2026/0027155 A1 · Compositions and methods related to potent cytotoxic m-cenk cells from cd3/cd14-depleted apheresis products

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0027155 A1
- Document ID: US20260027155A1
- Status: Published application
- Kind: A1
- Application number: 19/277,274
- Filed: 2025-07-22
- Published: 2026-01-29
- Earliest claimed: 2024-07-23
- Assignees: ImmunityBio, Inc.
- Applicants: ImmunityBio, Inc.
- Inventors: Ferdous Anower-E-Khuda; Gene Yeh; Syed Raza Ali; Manju Saxena; Leonard Sender; Patrick Soon-Shiong
- Web page: https://patentgrep.com/patent/US20260027155A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/42: Cancer antigens
- A61K 40/421: {Immunoglobulin superfamily}
- A61P 35/00: Antineoplastic agents
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 16/2887: {against CD20}
- C12N 5/0018: {Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C12N 2501/2312: Interleukin-12 (IL-12)
- C12N 2501/2315: Interleukin-15 (IL-15)
- C12N 2501/2318: Interleukin-18 (IL-18)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are compositions and methods related to potent cytotoxic M-CENK cells from CD3/CD14 depleted apheresis products.

## Claims

### Claim 1

A method of generating memory-like cytokine enhanced natural killer (M-CENK) cells from a blood sample, the method comprising:
(a) removing CD3+ cells and CD14+ cells from the blood sample to obtain a CD3− CD14− population of cells; and
(b) incubating the CD3− CD14− population of cells with a first cytokine composition comprising a stabilized IL-15 analog or fusion protein comprised thereof for a first period (optionally 8-10 days), and
(c) incubating the CD3− CD14− population of cells with a second cytokine composition comprising i) IL-15 or a stabilized derivative thereof, ii) IL-18 or a stabilized derivative thereof, and iii) IL-12 or a stabilized derivative thereof for a second period (optionally 14-16 hours), thereby producing a population of CD56+ enriched M-CENK cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the IL-15 or stabilized derivative thereof is in a concentration ranging from 25 to 175 ng/ml.

### Claim 3 (depends on 1)

The method of claim 1, wherein the IL-18 or stabilized derivative thereof is in a concentration ranging from 25 to 50 ng/ml.

### Claim 4 (depends on 1)

The method of claim 1, wherein the IL-12 or stabilized derivative thereof is in a concentration ranging from 5 to 10 ng/ml.

### Claim 5 (depends on 1)

The method of claim 1, wherein the blood sample is obtained from a cancer patient.

### Claim 6 (depends on 5)

The method of claim 5, wherein a cancer of the cancer patient is a small cell lung cancer, an ovarian cancer, a breast cancer, a leukemia, a myelogenous leukemia, or an acute lymphoblastic leukemia.

### Claim 7 (depends on 1)

The method of claim 1, wherein step (a) is by magnetic cell separation.

### Claim 8 (depends on 1)

The method of claim 1, wherein the first period lasts 7 to 12 days.

### Claim 9 (depends on 1)

The population of CD56+ enriched M-CENK cells produced from the method of claim 1.

### Claim 10 (depends on 9)

The population of CD56+ enriched M-CENK cells of claim 9, wherein greater than 90% of the cells are CD56+.

### Claim 11 (depends on 9)

The population of CD56+ enriched M-CENK cells of claim 9, wherein greater than 60% of the cells are CD16+.

### Claim 12

A method of treating a patient diagnosed with cancer, the method comprising:
(a) obtaining a blood sample from the patient;
(b) removing CD3+ cells and CD14+ cells from the blood sample to obtain a CD3− CD14− fraction;
(c) contacting the CD3− CD14− fraction with IL-15 or a stabilized derivative thereof for a first period of time;
(d) contacting the CD3− CD14− fraction with IL-12 or a derivative thereof, IL-18 or a derivative thereof, and IL-15 or a derivative thereof, for a second period of time, thereby obtaining a cell culture comprising a population of CD56+ enriched M-CENK cells;
(e) centrifuging the cell culture to produce a supernatant;
(f) isolating exosomes from the supernatant; and
(g) administering the isolated exosomes to the patient, thereby treating the cancer.

### Claim 13 (depends on 9)

A method of treating a patient diagnosed with cancer, the method comprising administering a therapeutically effective amount of the CD56+ enriched M-CENK cells of claim 9 to the patient.

### Claim 14 (depends on 12)

The method of claim 12, wherein the cancer is a solid tumor, optionally, the solid tumor is a metastatic solid tumor.

### Claim 15 (depends on 12)

The method of claim 12, wherein the cancer is a small cell lung cancer, an ovarian cancer, a breast cancer, a leukemia, a myelogenous leukemia, or a acute lymphoblastic leukemia.

### Claim 16 (depends on 12)

The method of claim 12, wherein greater than 90% of the CD56+ enriched population of cells are CD56+.

### Claim 17 (depends on 12)

The method of claim 12, wherein greater than 60% of the CD56+ enriched population of cells are CD16+.

### Claim 18 (depends on 12)

The method of claim 12, wherein the method further comprises administering an antibody.

### Claim 19 (depends on 18)

The method of claim 18, wherein the antibody is an anti-CD20 antibody.

### Claim 20

A kit for preparing CD56+M-CENK cell exosomes, the kit comprising: i) reagents for depleting CD3+ cells and CD14+ cells from a blood sample; ii) IL-15 or a fusion protein comprised thereof, iii) IL-12 or a fusion protein comprised thereof, and iv) IL-18 or a fusion protein comprised thereof.

### Claim 21

A population of CD56+ enriched M-CENK cells wherein at least 90% of the cells are CD3−, CD14−, and CD56+, and wherein at least 60% of the cells express CD16.

### Claim 22 (depends on 21)

The population of CD56+ enriched M-CENK cells of claim 21, wherein the cells are frozen and thawed.

### Claim 23

A cell culture mixture comprising a population of blood cells that are CD3− CD14−, a first cytokine composition comprising a stabilized IL-15 analog or fusion protein.

### Claim 24 (depends on 23)

The cell culture mixture of claim 23, further comprising a second cytokine composition comprising one or more of i) IL-15 or a stabilized derivative thereof, ii) IL-18 or a stabilized derivative thereof, and iii) IL-12 or a stabilized derivative thereof.
